Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug company focused on cardiovascular and metabolic diseases, has withdrawn registration for an $86.25 million IPO, due to “market conditions.” This is the second time in as many years that Aegerion has canceled a proposed IPO.
